Program
efruxifermin
Also written as “Efruxifermin” and “AMG 876”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Diabetes Mellitus, Type 2, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 43 open or running | phase 3since Nov 22, 2023 | Feb 16, 2021 | Feb 2030phase 3 · NCT06528314 |
| Amgen | 20 open or running | phase 1since Sep 28, 2011 | Sep 28, 2011 | none ahead |
- Named in Novo Nordisk’s own pipeline as
Efruxifermin in MASH
, phase 3, as of Nov 5, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 28, 2011First study: phase 1 study in Diabetes MellitusNew to AmgenAmgen · NCT01492465 · 47 enrolled · United States
- Mar 25, 2013Phase 1 study in Diabetes MellitusAmgen · NCT01856881 · 86 enrolled · United States
- Feb 16, 2021Novo Nordisk's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Novo NordiskNovo Nordisk · NCT04767529 · 128 enrolled · United States, Puerto Rico
- Nov 22, 2023Phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06161571 · 700 enrolled · United States, Argentina, Australia and more
- Dec 6, 2023Phase 3 study in NASH With FibrosisNovo Nordisk · NCT06215716 · 1,650 planned · United States, Argentina, Australia and more
- Jun 28, 2024Phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06528314 · 2,150 planned · United States, Argentina, Australia and more
Ahead
- Feb 2030Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseNovo Nordisk · NCT06528314
- Feb 2033Primary completion: phase 3 study in NASH With FibrosisNovo Nordisk · NCT06215716
TargetBeta
“A long-acting bivalent analog of fibroblast growth factor 21 (FGF21) and fusion protein composed of human immunoglobulin G1 (IgG1) Fc domain attached to a modified form of FGF21, with metabolic regulating, anti-diabetic, and anti-fibrotic activities. Upon administration, efruxifermin mimics FGF21…”NCIt, read by Claude
Other programs on FGF21
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| efimosfermin alfa | GlaxoSmithKline | phase 3 | 10 |
| pegozafermin | 89bio-inc | phase 3 | 8 |
| zalfermin | Novo Nordisk | phase 2 | 10 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06528314Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Recruiting | Novo Nordisk | Feb 2030 | 2,150 |
| NCT06215716NASH With Fibrosis · United States, Argentina, Australia and more | 3 | Recruiting | Novo Nordisk | Feb 2033 | 1,650 |
| NCT06161571Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novo Nordisk | Mar 3, 2026 | 700 |
| NCT04767529Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 2 | Completed | Novo Nordisk | May 2, 2024 | 128 |
| NCT01856881Diabetes Mellitus · United States | 1 | Terminated | Amgen | Nov 2014 | 86 |
| NCT01492465Diabetes Mellitus · United States | 1 | Terminated | Amgen | Jul 2012 | 47 |
How it is read
Names in the registry
- “Efruxifermin”, 4 entries
- “AMG 876”, 2 entries
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 3 studies
- Diabetes Mellitus, Type 2, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.